drugset
drugset / Trial / NCT06441968

Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults

NCT06441968 ↗

Phase 1 Completed 60 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
Non-randomizedSequentialOpen-labelPrevention

Summary

A clinical trial to evaluate the safety, reactogenicity, and immunogenicity of MPV/S-2P administered intranasally to adults who have previously received a primary series and at least one booster with an authorized or licensed mRNA SARS-CoV-2 parenteral vaccine. The primary objective is to evaluate the safety and reactogenicity of a single dose of MPV/S-2P in previously vaccinated healthy adults.

Timeline

Start
2024-07-01
Primary completion
2025-11-12
Completion
2025-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MPV/S-2P Vaccine 10000 unknown Intranasal
Subject MPV/S-2P Vaccine 100000 unknown Intranasal
Subject MPV/S-2P Vaccine 1e+06 unknown Intranasal

Indications

COVID-19